Kazia Therapeutics shares are trading higher after the company announced it received FDA Fast Track Designation for its lead program, paxalisib.
Portfolio Pulse from Benzinga Newsdesk
Kazia Therapeutics has received FDA fast track designation for its lead program, Paxalisib, leading to a rise in its share prices.
July 06, 2023 | 12:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kazia Therapeutics' stock is trading higher after the FDA fast track designation for its lead program, Paxalisib.
The FDA fast track designation is a significant regulatory milestone that can expedite the development and review of a drug. This news is likely to boost investor confidence in Kazia Therapeutics, leading to a short-term increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100